Carl Zeiss Meditec

At the Asia-Pacific summit in Seoul, Carl Zeiss CEO Andreas Pecher emphasized that Zeiss is expanding its innovation and market proximity in South Korea and recently opened a new research center to better serve customers like Samsung and SK Hynix. Corporate leaders are calling for a more pragmatic German industrial policy as value chains diversify amid the AI boom and geopolitical tensions. Many companies still view China as an important market but also see opportunities in South Korea, ASEAN countries and India; at the same time managers warn that Germany’s relative cost and growth disadvantages make investment more difficult. » Więcej na faz.net

Under CEO Andreas Pecher, Carl Zeiss is consolidating an ambitious cost-cutting program with annual savings of “several hundred million” over three years to free up funds for the innovation program “Beyond.” The focus remains the semiconductor division, supplying high-end projection optics for ASML, while the group is also seeking new future fields such as spatial biology, photonics and precision farming. Restructuring measures include divestments (e.g., sports optics) and staffing adjustments; up to 700 jobs worldwide in the medical technology unit could be affected. The goal is to make Zeiss grow profitably in the long term and to provide resources for scalable, market-ready innovations. » Więcej na faz.net

Bronwyn Brophy O'Connor will succeed Andreas Pecher as CEO of Carl Zeiss Meditec on December 1. At the same time she will join the management board of the parent company and take responsibility for its medical technology division. The executive previously worked at Vitrolife, brings more than 25 years of industry experience and has worked for Thermo Fisher and Medtronic, among others; Pecher had recently launched a cost‑saving program that could cut up to 1,000 jobs. » Więcej na wiwo.de

After a sell recommendation from Goldman Sachs, Carl Zeiss Meditec’s stock came under pressure and fell intraday by as much as around 7 percent, but remained just above the 200-day line at €28.98 and later reduced the loss to about 2 percent. Goldman Sachs justified the downgrade with further deteriorated sales prospects and the assessment that these risks were not yet sufficiently reflected in the valuation. The stock is down more than 20 percent year-to-date. » Więcej na finanzen.net

Carl Zeiss Meditec has received 510(k) clearance from the US FDA for ZEISS CLINIC 360, a cloud- and browser-based software that consolidates diagnostic imaging data, EMR, and practice management systems into a unified patient view. The solution integrates data from ZEISS devices and DICOM-capable third-party devices and offers tools for monitoring glaucoma progression, trend analysis, and case/report exchange via “ZEISS Collaborative Care.” ZEISS CLINIC 360 will be available by subscription in the US from early fall 2026; ZEISS FORUM will remain available for users who prefer on-premise solutions. The product is not approved for use in humans in the EU. » Więcej na de.investing.com